

**Table SIII. Baseline demographics and disease characteristics (fast responders to Psoriasis Area and Severity Index (PASI) 90 cohort)**

	PASI90FR at week 4 n = 103	PASI90NFR at week 4 n = 318	p-value
Age (years), mean (SD)	42.72 (13.76)	45.86 (12.86)	<b>0.03</b>
Male, n (%)	69 (66.99)	235 (73.90)	0.17
Caucasian, n (%)	100 (97.09)	315 (99.06)	0.11
Weight, kg, mean (SD)	77.76 (16.52)	82.13 (16.89)	<b>0.02</b>
Height, cm, mean (SD)	171.44 (9.37)	172.33 (9.12)	0.40
Body mass index, kg/m <sup>2</sup> , mean (SD)	26.41 (5.10)	27.63 (5.26)	<b>0.04</b>
Body mass index ≥ 25 kg/m <sup>2</sup> , n (%)	58 (56.31)	210 (66.04)	0.07
Waist, cm, mean (SD)	94.43 (16.13)	97.12 (14.73)	0.13
Smoking status, n (%)			
Current	50 (48.54)	148 (46.54)	
Former	15 (14.56)	46 (14.47)	
Never	38 (36.89)	124 (38.99)	0.92
Type of psoriasis other than plaque, n (%)			
Nail	34 (33.01)	131 (41.19)	0.14
Scalp	77 (74.76)	254 (79.87)	0.27
Age at psoriasis diagnosis, years, mean (SD)	24.41 (14.37)	28.17 (13.57)	<b>0.007</b>
Time since psoriasis diagnosis, years, mean (SD)	18.88 (12.48)	18.27 (11.66)	0.77
Presence of psoriatic arthritis, n (%)	15 (14.56)	68 (21.38)	0.13
Time since psoriatic arthritis diagnosis, years, mean (SD)	4.35 (3.93)	9.61 (8.74)	0.02
Psoriasis Area and Severity Index score, mean (SD)	22.04 (10.46)	20.91 (9.37)	0.30
Investigator's Global Assessment 2011 modification, n (%)			
Mild	6 (5.83)	6 (1.89)	
Moderate	57 (55.34)	168 (52.83)	
Severe	40 (38.83)	144 (45.28)	0.08
Metabolic syndrome, n (%)	15 (14.56)	56 (17.61)	0.47
Cw6 positive, n (%)	51 (49.51)	127 (39.94)	0.08
Prior biologic systemic therapy for psoriasis, n (%)	20 (19.42)	100 (31.45)	<b>0.02</b>
At least one comorbidity, n (%)	63 (61.17)	205 (64.47)	0.55

PASI90FR: PASI 90 fast responders; PASI90NFR: PASI 90 non-fast responders; SD: standard deviation. Those values that are statistically significant are highlighted in bold.